MHRA APPROVES REMIBRUTINIB FOR ADULTS WITH CHRONIC SPONTANEOUS URTICARIA
REPORT A PROBLEM WITH THIS SOURCE
WHAT HAPPENED
As with any medicinal product, the MHRA will keep the safety and effectiveness of remibrutinib under close review.
News and communications reports that as with any medicinal product, the MHRA will keep the safety and effectiveness of remibrutinib under close review.
The current RSS excerpt provides limited detail. The most useful way to read a developing report is to separate the confirmed detail from early claims, then follow the next named source or decision. The original report remains essential for names, figures, and full context.
This is a developing report. DAMMNEWS will surface related coverage as closely matched reporting enters the live cache.
DAMMNEWS RSS BRIEFING — generated locally from the available News and communications headline and RSS excerpt. It is not a summary of the full source article.
RELATED DAMMNEWS COVERAGE
- VERSATILE VALKYRIES GUARD VERONICA BURTON HELPS SECOND-YEAR FRANCHISE CHALLENGE WNBA ELITES
Associated Press • 7 mins ago • TOP - SCOTTISH FA SCRAPS KEY MATCH INCIDENT PANEL
BBC Sport • 34 mins ago • SPORT - ROMANIA RUSHES TO SINK 4 BARGES IN THE DANUBE TO KEEP A NUCLEAR POWER PLANT’S SECOND REACTOR RUNNING
Associated Press • 37 mins ago • TOP